Search results
Showing 1 to 15 of 284 results for coronavirus
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Awaiting development [GID-TA10721] Expected publication date: TBC
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
Show all sections
All NICE products on COVID-19. Includes any guidance and advice.
Management of emergency department patients during the COVID-19 pandemic (Word)
management during the COVID 19pandemicClinical guide for the management of emergency departmentpatients during the...
Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)
This information sets out the process and methods used to develop rapid guidelines on COVID-19.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
In development [GID-TA11352] Expected publication date: TBC
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
A multi-agency collaboration to get treatments for COVID-19 to patients quickly